US 12,265,084 B2
Method for analyzing the platelets of a blood sample
Blandine Maitre, Strasbourg (FR); Catherine Angenieux, Strasbourg (FR); Henri De La Salle, Strasbourg (FR); and Christian Gachet, Lalaye (FR)
Assigned to ETABLISSEMENT FRANCAIS DU SANG, Saint-Denis (FR); INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), Paris (FR); and UNIVERSITE DE STRASBOURG, Strasbourg (FR)
Appl. No. 17/263,269
Filed by ETABLISSEMENT FRANCAIS DU SANG, Saint-Denis (FR); INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), Paris (FR); and UNIVERSITE DE STRASBOURG, Strasbourg (FR)
PCT Filed Jul. 29, 2019, PCT No. PCT/FR2019/051867
§ 371(c)(1), (2) Date Jan. 26, 2021,
PCT Pub. No. WO2020/025891, PCT Pub. Date Feb. 6, 2020.
Claims priority of application No. 1857095 (FR), filed on Jul. 30, 2018.
Prior Publication US 2021/0148919 A1, May 20, 2021
Int. Cl. G01N 33/58 (2006.01); G01N 33/49 (2006.01)
CPC G01N 33/582 (2013.01) [G01N 33/4915 (2013.01); G01N 2800/222 (2013.01); G01N 2800/32 (2013.01); G01N 2800/50 (2013.01); G01N 2800/52 (2013.01)] 20 Claims
 
1. A process for analyzing platelets present in a blood sample, said process comprises the steps of:
a) obtaining a fluorochrome-coupled ligand that binds to MHC I expressed on said platelets present in said blood sample;
b) adding the fluorochrome-coupled ligand to said sample;
c) measuring a mean fluorescence intensity of the platelets (MFIplatelets) with a flow cytometer; and
d) measuring a mean forward scatter (FSC) parameter with said flow cytometer and determining a MFIplatelets/FSC ratio.